Tags

Type your tag names separated by a space and hit enter

Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens.
Ann Rheum Dis 2015; 74(5):851-8AR

Abstract

OBJECTIVE

To determine if the dietary supplements, glucosamine and/or chondroitin, result in reduced joint space narrowing (JSN) and pain among people with symptomatic knee osteoarthritis.

METHODS

A double-blind randomised placebo-controlled clinical trial with 2-year follow-up. 605 participants, aged 45-75 years, reporting chronic knee pain and with evidence of medial tibio-femoral compartment narrowing (but retaining >2 mm medial joint space width) were randomised to once daily: glucosamine sulfate 1500 mg (n=152), chondroitin sulfate 800 mg (n=151), both dietary supplements (n=151) or matching placebo capsules (n=151). JSN (mm) over 2 years was measured from digitised knee radiographs. Maximum knee pain (0-10) was self-reported in a participant diary for 7 days every 2 months over 1 year.

RESULTS

After adjusting for factors associated with structural disease progression (gender, body mass index (BMI), baseline structural disease severity and Heberden's nodes), allocation to the dietary supplement combination (glucosamine-chondroitin) resulted in a statistically significant (p=0.046) reduction of 2-year JSN compared to placebo: mean difference 0.10 mm (95% CI 0.002 mm to 0.20 mm); no significant structural effect for the single treatment allocations was detected. All four allocation groups demonstrated reduced knee pain over the first year, but no significant between-group differences (p=0.93) were detected. 34 (6%) participants reported possibly-related adverse medical events over the 2-year follow-up period.

CONCLUSIONS

Allocation to the glucosamine-chondroitin combination resulted in a statistically significant reduction in JSN at 2 years. While all allocation groups demonstrated reduced knee pain over the study period, none of the treatment allocation groups demonstrated significant symptomatic benefit above placebo.

TRIAL REGISTRATION CLINICALTRIALSGOV IDENTIFIER

NCT00513422; http://www.clinicaltrials.gov.

Authors+Show Affiliations

Faculty of Health Sciences, University of Sydney, Lidcombe, New South Wales, Australia.Faculty of Health Sciences, University of Sydney, Lidcombe, New South Wales, Australia.Faculty of Health Sciences, University of Sydney, Lidcombe, New South Wales, Australia.Graduate School of Medicine, Notre Dame University, Darlinghurst, New South Wales, Australia.Faculty of Health Sciences, University of Sydney, Lidcombe, New South Wales, Australia.Covance Pty Ltd, Sydney, New South Wales, Australia.The George Institute for Global Health, University of Sydney, Camperdown, New South Wales, Australia.Institute of Bone and Joint Research, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia.St George Hospital Clinical School, University of New South Wales, Kogarah, New South Wales, Australia.The George Institute for Global Health, University of Sydney, Camperdown, New South Wales, Australia.The George Institute for Global Health, University of Sydney, Camperdown, New South Wales, Australia.Department of Clinical Pharmacology, St Vincent's Hospital and University of New South Wales, Darlinghurst, New South Wales, Australia.No affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24395557

Citation

Fransen, Marlene, et al. "Glucosamine and Chondroitin for Knee Osteoarthritis: a Double-blind Randomised Placebo-controlled Clinical Trial Evaluating Single and Combination Regimens." Annals of the Rheumatic Diseases, vol. 74, no. 5, 2015, pp. 851-8.
Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74(5):851-8.
Fransen, M., Agaliotis, M., Nairn, L., Votrubec, M., Bridgett, L., Su, S., ... Day, R. (2015). Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Annals of the Rheumatic Diseases, 74(5), pp. 851-8. doi:10.1136/annrheumdis-2013-203954.
Fransen M, et al. Glucosamine and Chondroitin for Knee Osteoarthritis: a Double-blind Randomised Placebo-controlled Clinical Trial Evaluating Single and Combination Regimens. Ann Rheum Dis. 2015;74(5):851-8. PubMed PMID: 24395557.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. AU - Fransen,Marlene, AU - Agaliotis,Maria, AU - Nairn,Lillias, AU - Votrubec,Milana, AU - Bridgett,Lisa, AU - Su,Steve, AU - Jan,Stephen, AU - March,Lyn, AU - Edmonds,John, AU - Norton,Robyn, AU - Woodward,Mark, AU - Day,Richard, AU - ,, Y1 - 2014/01/06/ PY - 2013/05/15/received PY - 2013/12/14/accepted PY - 2014/1/8/entrez PY - 2014/1/8/pubmed PY - 2015/7/3/medline KW - chondroitin KW - disease progression KW - glucosamine KW - osteoarthritis knee KW - pain SP - 851 EP - 8 JF - Annals of the rheumatic diseases JO - Ann. Rheum. Dis. VL - 74 IS - 5 N2 - OBJECTIVE: To determine if the dietary supplements, glucosamine and/or chondroitin, result in reduced joint space narrowing (JSN) and pain among people with symptomatic knee osteoarthritis. METHODS: A double-blind randomised placebo-controlled clinical trial with 2-year follow-up. 605 participants, aged 45-75 years, reporting chronic knee pain and with evidence of medial tibio-femoral compartment narrowing (but retaining >2 mm medial joint space width) were randomised to once daily: glucosamine sulfate 1500 mg (n=152), chondroitin sulfate 800 mg (n=151), both dietary supplements (n=151) or matching placebo capsules (n=151). JSN (mm) over 2 years was measured from digitised knee radiographs. Maximum knee pain (0-10) was self-reported in a participant diary for 7 days every 2 months over 1 year. RESULTS: After adjusting for factors associated with structural disease progression (gender, body mass index (BMI), baseline structural disease severity and Heberden's nodes), allocation to the dietary supplement combination (glucosamine-chondroitin) resulted in a statistically significant (p=0.046) reduction of 2-year JSN compared to placebo: mean difference 0.10 mm (95% CI 0.002 mm to 0.20 mm); no significant structural effect for the single treatment allocations was detected. All four allocation groups demonstrated reduced knee pain over the first year, but no significant between-group differences (p=0.93) were detected. 34 (6%) participants reported possibly-related adverse medical events over the 2-year follow-up period. CONCLUSIONS: Allocation to the glucosamine-chondroitin combination resulted in a statistically significant reduction in JSN at 2 years. While all allocation groups demonstrated reduced knee pain over the study period, none of the treatment allocation groups demonstrated significant symptomatic benefit above placebo. TRIAL REGISTRATION CLINICALTRIALSGOV IDENTIFIER: NCT00513422; http://www.clinicaltrials.gov. SN - 1468-2060 UR - https://www.unboundmedicine.com/medline/citation/24395557/Glucosamine_and_chondroitin_for_knee_osteoarthritis:_a_double_blind_randomised_placebo_controlled_clinical_trial_evaluating_single_and_combination_regimens_ L2 - http://ard.bmj.com/cgi/pmidlookup?view=long&pmid=24395557 DB - PRIME DP - Unbound Medicine ER -